Register November 2019 No. 767
Chapter CSB 2
ADDITIONS TO SCHEDULES IN SS. 961.14,
961.16, 961.18, 961.20 AND 961.22, STATS.
Addition of methaqualone to schedule II.
Addition of benzphetamine, chlorphentermine, clortermine, mazindol, and phendimetrazine to schedule III.
Addition of fenfluramine to schedule IV.
Addition of amobarbital, pentobarbital, and secobarbital to schedule II; retention of certain forms of amobarbital, pentobarbital and secobarbital in schedule III.
Addition of drotebanol to schedule I.
Addition of pentazocine to schedule III.
Transfer of hydrochloride form of etorphine from schedule I to schedule II.
Addition of poppy straw to schedule II, addition of pemoline and mebutamate to schedule IV.
Additions to schedules IV and I.
Addition of propiram to schedule I.
Renumbering and addition to schedule IV of diethylpropion and phentermine.
Addition of dextropropoxyphene to schedule IV.
Addition of prazepam to schedule IV.
Addition of parahexyl to schedule I; removal of loperamide from schedule V; addition of triazolam to schedule IV.
Transfer of sufentanil from schedule I to schedule II.
Addition of buprenorphine to schedule V; transfer of methaqualone from schedule II to schedule I; transfer of dronabinol from schedule I to schedule II.
Addition of 3,4-methylenedioxymethamphetamine to schedule I.
Additions, deletions and transfers to statutory schedules.
Addition of beta-hydroxy-3-methylfentanyl to schedule I.
Additions, deletions, corrections, transfers, and amendments to drug schedules.
Additions to drug schedules.
Additions and amendments to drug schedules.
Addition of butorphanol to schedule IV.
Addition of remifentanil to schedule II; transfer of dronabinol from schedule II to schedule III; addition of fenproporex, modafinil, sibutramine, zaleplon and zolpidem to schedule IV; spelling correction of carfentanil.
Addition of dihydroetorphine to schedule II.
Addition of dichloralphenazone to schedule IV.
Transfer of buprenorphine from schedule V to schedule III.
Addition of gamma-hydroxybutyric acid to schedule III.
Addition of 2,5 dimethoxy-4-(n)- propylthiophenethylamine (2C-T-7) to schedule I.
Addition of N- benzylpiperazine (BZP) to schedule I.
Addition of alpha-methyltryptamine (AMT) to schedule I.
Addition of 5-methoxy-N, N-diisopropyltryptamine (5-MeO-DIPT).
Addition of lisdexamfetamine to schedule II.
Addition of tramadol to schedule IV.
Rescheduling of hydrocodone combination products.
Addition of suvorexant to schedule IV.
Exclusion of naloxegol.
Exclusion of [123I]ioflupane.
Scheduling of beta-hydroxythiofentanyl and butyryl fentanyl.
Scheduling of furanyl fentanyl.
Addition of brivaracetam to schedule V.
Addition of thiafentanil to schedule II.
Addition of AB-FUBINACA and ADB-PINACA to schedule I.
Addition of acetyl fentanyl to schedule I.
Addition of AH-7921 to schedule I.
Addition of eluxadoline to schedule IV.
Addition of U-47700 to schedule I.
Addition of AB-CHMINACA, AB-PINACA and THJ-2201 to schedule I.
Addition of MAB-CHMINACA to schedule I.
Addition of 4-MePPP and a-PBP to schedule I.
Scheduling of acryl fentanyl.
Addition of oral solutions containing dronabinol to schedule II.
Addition of 5F-ADB, 5F-AMB, ADB-FUBINACA, MDMB-CHMICA and MDMB-FUBINACA to schedule I.
Addition of 4-fluoroisobutyryl fentanyl to schedule I.
Scheduling of cyclopropyl fentanyl.
Exclusion of naldemedine.